🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

187 results for “Roche” Clear

  1. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Roche Registration Limited

    Healthy volunteers

    phase 1 other active

    1 trial

  2. A study investigating the safety, absorption, and elimination of RO7795068, a new compound that may potentially be used in the treatment of obesity

    Roche Registration Limited

    Not Applicable

    phase 1 other active

    1 trial

  3. A study investigating the safety, absorption, and elimination of RO7795081, a new compound that may potentially be used in the treatment of type 2 diabetes and weight control

    Roche Registration Limited

    Not Applicable

    phase 1 other active

    1 trial

  4. A study investigating the safety, absorption, and elimination of radioactively labeled RO7269162, a new compound that may potentially be used in the treatment of Alzheimer’s disease.

    Roche Registration Limited

    Healthy males volunteers

    phase 1 other active

    1 trial

  5. A study to evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and preliminary Anti-Tumor activity of RO7616789 in participants with Advanced Small Cell Lung Cancer and other Neuroendocrine Carcinomas

    Roche Registration Limited

    Small Cell Lung Cancer and Neuroendocrine Carcinoma

    phase 1 other active

    1 trial

  6. A study to see how RO7763505 works and how safe it is when given to healthy people and people with stable heart disease

    Roche Registration Limited

    Stable Coronary Artery Disease (CAD)

    phase 1 other active

    1 trial

  7. A study to test the biological properties of RO7568282 and whether it is safe in healthy participants and participants with Parkinson’s disease.

    Roche Registration Limited

    Parkinson’s Disease

    phase 1 other active

    1 trial

  8. An Early-Stage Study in Multiple Clinics of how Afimkibart May Affect the Body’s Processing of Medicines that Rely on Cytochrome P450 Enzymes in Patients with Ulcerative Colitis

    Roche Registration Limited

    Active Ulcerative Colitis (UC)

    phase 1 other active

    1 trial

  9. An early Phase 1b Study to assess how safe and effective is the treatment with drugs, called Mosunetuzumab or Glofitamab in Combination with drugs called, CC-220 and CC-99282 in Patients with B-Cell Non-Hodgkin Lymphoma.

    Roche Registration Limited

    Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  10. First-in-Human Study of RO7812653

    Roche Registration Limited

    Early Symptomatic Alzheimer’s Disease (eAD), (Mild Cognitive Impairment due to AD, or probable AD dementia)

    phase 1 other active

    1 trial

  11. Liberase Enzyme (Roche)

    Black Diamond Therapeutics

    Pulmonary Alveolar Proteinosis

    phase 1 small molecule active

    1 trial

  12. Multiple Dose Study of RO7795068 and its effect on Gastric Emptying, and on PK of Oral Contraceptives

    Roche Registration Limited

    Healthy Overweight or Obese

    phase 1 other active

    1 trial

  13. Rugonersen

    Roche Registration Limited

    Angelman Syndrome (AS)

    phase 1 small molecule active

    1 trial

  14. Tiragolumab, CISPLATIN , Tecentriq 1 200 mg concentrate for solution for infusion, GEMCITABINE

    Roche Registration Limited

    Urothelial carcinoma (UC)

    phase 1 small molecule active

    1 trial

  15. Evrysdi 0.75 mg/mL powder for oral solution, RO7034067

    Roche Registration Limited

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial

  16. Hemlibra 150 mg/mL solution for injection

    Roche Registration Limited

    Severe or Moderate Hemophilia A

    approved small molecule active

    1 trial

  17. Ocrevus 300 mg concentrate for solution for infusion

    Roche Registration Limited

    Multiple Sclerosis (MS) or Clinically Isolated Syndrome (CIS) [in line with the locally approved indications]

    approved small molecule active

    1 trial

  18. RO7034067, Evrysdi 0.75 mg/mL powder for oral solution

    Roche Registration Limited

    Spinal Muscular Atrophy (SMA)

    approved small molecule active

    1 trial

  19. Vabysmo 120 mg/mL solution for injection

    Roche Registration Limited

    Neovascular Age-Related Macular Degeneration

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources